Home » Stocks » Fortress Biotech

Fortress Biotech, Inc. (FBIO)

Stock Price: $2.65 USD -0.03 (-1.12%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $2.58 -0.07 (-2.64%) Oct 23, 7:54 PM

Stock Price Chart

Key Info

Market Cap 233.22M
Revenue (ttm) 43.28M
Net Income (ttm) -53.94M
Shares Out 88.01M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $2.65
Previous Close $2.68
Change ($) -0.03
Change (%) -1.12%
Day's Open 2.68
Day's Range 2.58 - 2.73
Day's Volume 928,264
52-Week Range 1.04 - 4.78

More Stats

Market Cap 233.22M
Enterprise Value 144.35M
Earnings Date (est) Nov 6, 2020
Ex-Dividend Date n/a
Shares Outstanding 88.01M
Float 64.60M
EPS (basic) -1.29
EPS (diluted) -0.87
FCF / Share -1.21
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.17M
Short Ratio 1.34
Short % of Float 3.36%
Beta 2.20
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 5.39
PB Ratio 3.86
Revenue 43.28M
Operating Income -99.85M
Net Income -53.94M
Free Cash Flow -83.10M
Net Cash 88.87M
Net Cash / Share 1.01
Gross Margin 60.30%
Operating Margin -230.71%
Profit Margin -124.60%
FCF Margin -192.02%
ROA -25.17%
ROE -106.89%
ROIC -33.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.79*
(231.70% upside)
Low
4.75
Current: $2.65
High
15.00
Target: 8.79
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue36.6326.8817.2516.480.86-----
Revenue Growth36.26%55.88%4.64%1809.62%------
Gross Profit26.1020.7613.5915.690.86-----
Operating Income-111-120-89.80-65.71-50.53-20.65-35.78-27.18-35.04-8.51
Net Income-39.96-84.15-66.88-55.10-48.43-20.39-37.16-27.61-36.36-9.98
Shares Outstanding54.7143.4641.6639.9639.1536.3230.4321.657.664.45
Earnings Per Share-0.73-1.94-1.61-1.38-1.24-0.56-1.22-1.27-5.51-2.24
Operating Cash Flow-94.96-98.85-81.31-45.81-20.38-16.33-29.65-23.19-10.95-5.68
Capital Expenditures-2.35-7.08-0.65-6.37-0.28--0.04-0.05--0.01
Free Cash Flow-97.31-106-81.95-52.18-20.66-16.33-29.69-23.25-10.95-5.69
Cash & Equivalents15399.1914710811384.3599.5240.2023.1614.86
Total Debt11079.5062.5028.5123.1714.0013.2214.190.75-
Net Cash / Debt43.2819.6884.4679.7189.5970.3486.3026.0122.4114.86
Assets22614124617111989.3310140.9923.3814.94
Liabilities15412112587.7634.3418.8019.3018.964.241.56
Book Value26.221.8552.5738.5056.8570.5281.2822.0319.13-15.90
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Fortress Biotech, Inc.
Country United States
Employees 93
CEO Lindsay Allan Rosenwald

Stock Information

Ticker Symbol FBIO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: FBIO

Description

Fortress Biotech develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial that reduces amyloid deposits in the tissues and organs; CD123 chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; CD20 CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, the company develops MB-101 for Glioblastoma multiform (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB 108 for GBM; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101, a Phase I clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; Cosibelimab, a Phase I clinical trial for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; AVTS-001, an adeno-associated virus gene therapy; CUTX-101, a copper histidinate injection for the treatment of Menkes disease; CK-103 for metastatic solid tumor cancers; CK-302 for oncology indications; and CK-303 to treat renal cell carcinoma. It has collaboration arrangements with some universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.